The primary outcome was a composite of ischemic stroke, myocardial infarction (MI), or death resulting from an ischemic vascular event up to 90 days, with a secondary safety end point of major hemorrhage during the same time period. Compared with aspirin alone, aspirin plus clopidogrel resulted in fewer 0.4%; HR, 2.32 [95% CI, 1.10 4.87]; P=0.02). Overall, the beneficial effect of aspirin plus clopidogrel was driven by a reduction in ischemic stroke (HR, 0.72 [95% CI, 0.56 0.92]; P=0.01) and greatest in the first 30 days of treatment from symptom onset (HR, 0.73 [95% CI, 0.56 0.95]; P=0.02). However, the risk of major hemorrhage was greatest after the first 7 days of treatment (HR, 2.69 [95% CI, 1.05 6.86]; P=0.04). There was no significant added benefit of aspirin plus clopidogrel after 30 days of treatment. In addition, in a prespecified analysis of functional outcomes determined by 90- day mRS score 2 for new disability, there was no difference between groups (HR, 0.97 [95% CI, 0.82 1.14]; P=0.71). See Table XLVIII in online Data Supplement 1. The efficacy of the IV glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in the treatment of AIS is not well established. IIb B-R Recommendation revised from 2013 AIS Guidelines. Prospective, randomized, open-label phase II trials of tirofiban217 have suggested safety for treatment in patients with AIS. Single-arm studies of eptifibatide as adjunctive therapy to IV alteplase support ongoing RCTs to establish safety and efficacy.173,174 Further trials are necessary to clarify the safety and efficacy of this intervention. See Tables XXXIX and XLVIII in online Data Supplement 1. Ticagrelor is not recommended over aspirin for treatment of patients with minor acute stroke. III: No Benefit B-R New recommendation. 